SCHEMBL6484255

SCHEMBL6484255

Cc1ccc(Cl)cc1N(S)C(=O)Nc1nc(C)c(C)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
POLB P06746 1/20 0.52
FFAR2 O15552 1/20 0.47
NPC1 O15118 8/20 0.43
PKM P14618 2/20 0.43
MAPT P10636 5/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
RXFP1 Q9HBX9 2/20 0.41
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
ALDH1A1 P00352 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
DYRK1A Q13627 1/20 0.39
FSCN1 Q16658 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483433 0.82 SMN1; SMN2 (0.51) RAB9ASMN1; SMN2POLBNPC1PKM
SCHEMBL6496182 0.81 GCK (0.53) RAB9ASMN1; SMN2POLBFFAR2NPC1
SCHEMBL6486115 0.79 KCNMA1 (0.50) RAB9ASMN1; SMN2POLBFFAR2NPC1
SCHEMBL6491670 0.79 CASP3 (0.41) RAB9ASMN1; SMN2POLBNPC1MAPT
SCHEMBL6483409 0.78 RAB9A (0.53) RAB9ASMN1; SMN2POLBNPC1PKM
SCHEMBL6483601 0.75 SMARCA2 (0.44) RAB9ASMN1; SMN2POLBNPC1PKM
SCHEMBL6481744 0.74 TRPV1 (0.48) RAB9ASMN1; SMN2POLBNPC1MAPT
SCHEMBL8491551 0.74 PTK2 (0.51) RAB9ASMN1; SMN2NPC1PKMMAPT
SCHEMBL6495267 0.74 LMNA (0.36) SMN1; SMN2POLBMAPTKMT2AMEN1
SCHEMBL6496483 0.74 LMNA (0.53) RAB9ASMN1; SMN2POLBNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936630-B2 Substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents WYETH (US) 2005-08-30 US disclosed
US-20040127526-A1 Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents WYETH 2004-07-01 US disclosed
US-6686476-B2 ANTICHOILESTEROL AGENTS; CARDIOVASCULAR DISORDERS WYETH 2004-02-03 US disclosed
US-20030013747-A1 Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents WYETH 2003-01-16 US disclosed
US-6455566-B1 Substituted 1-aryl-3-heteroaryl-thioureas (or isothioureas) as antiatherosclerotic agents WYETH 2002-09-24 US disclosed
WO-1999011638-A1 SUBSTITUTED 1-ARYL-3- HETEROARYL-THIOUREAS AND SUBSTITUTED 1-ARYL-3-HETEROARYL-ISOTHIOUREAS AS ANTIATHEROSCLEROTIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013747-A1 Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents CBR1, LDLR, HMGCR RAB9A 1003/4885SMN1; SMN2 4763/4885POLB 3509/4885
US-20040127526-A1 Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents CBR1, LDLR, HMGCR RAB9A 1003/4885SMN1; SMN2 4763/4885POLB 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.